Active day of learning and discussion with a Round Up from Day 3 of #EULAR2024 with @RheumNow https://t.co/yzLsPNDM5d

#EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow https://t.co/Z4pujQRQ9h https://t.co/QRUnJInblH

#EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x

SLE Preview: abolishing refractory with CAR-T and better B-cell therapies Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years. https://t.co/778buNUq1C https://t.co/4ub8VbrLb6

#EULAR2024 OP0193 Watch out, blinatumomab will BiTE! Bi-specific T-cell engagers (BiTEs), kill Bcells by engaging Tcells. In 6 refractory #RA patients (failed 3 x ts/bDMARDs), deep blood & tissue depletion were met, good response. Brief raised temp but no cytokine storm @RheumNow https://t.co/OmxSbTXfZq

Fascinating - @ndb_org installed an app to measure smartphone usage, and texting less and moving less were associated with more flares. The pseudo-wearable in our pockets?? #EULAR2024 POS0678 @RheumNow https://t.co/ZA0hd3Q10d

RA patients on abatacept have an appalling immunogenic response to Shingrix. Humoral fades away in the first year, and an absence of cellular responses. Alarming and need strategies to combat this #EULAR2024 POS0620 Winthrop/@RADoctor @RheumNow https://t.co/8gY9ocLBDp

If your GCA flares, do you get the same features as you did at diagnosis? 20% of the time it can be new, so keep on doing the checklist! (also, visual flares uncommon - the power of pred) #EULAR2024 POS0110 @MayoClinic @MdWarrington @RheumNow https://t.co/hkF8vJT6HI

#EULAR2024 POS0390 What impact of regulatory warning on JAK-i on access to therapy? Data from UK BSSR-BR reported 4 in 5 #RA patients would have been considered ‘high-risk’. Of these, 28% had failed ≥3 biologics; so no suitable alternatives. Enormously impacted @RheumNow https://t.co/XeS9qHXSpH

What psychosocial factors drive treatment outcomes and disease activity for people living with rheumatoid arthritis? #EULAR2024 POS0309-PARE @DrMiniDey @ElenaNikiUK @RheumNow https://t.co/q0tTLSL044